Selpercatinib

6 trials 2 recruiting LOncology Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

3 Completed trials

5 Sponsors

8 Countries

Phase II

Phase I/II

Phase IV

Phase I (FiH)

Phase II: 3 Phase I/II: 1 Phase IV: 1 Phase I (FiH): 1

Oversight events:

1 serious breach 2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Medullary thyroid cancer 2 Central nervous system neoplasm 1 Non-small cell lung cancer 1

Sponsors using this IMP

Loxo Oncology Inc. 2 Eli Lilly & Co. 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Oslo University Hospital HF 1 Region Hovedstaden 1

All trials

6 total

Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tu… Ended

2023-507703-63-00 Phase I/II 5 countries Loxo Oncology Inc.
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged … Ended

2023-507678-42-00 Phase IV 4 countries Eli Lilly & Co.
A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumors. Ended

2023-507702-13-00 Phase I (FiH) 5 countries Loxo Oncology Inc.

Showing 1–6 of 6 trials

← All drugs A–Z